Advertisement

Efficacy and safety of triamterene/ hydrochlorothiazide combinations in mild systemic hypertension

  • Harold W. Schnaper
    Correspondence
    Address for reprints: Harold W. Schnaper, MD, Center for Aging, University of Alabama, 933 South 19th Street, UAB Station CHSB #201, Birmingham, Alabama 35294.
    Affiliations
    From the Department of Medicine and the Center for Aging, University of Alabama, Birmingham, Alabama U.S.A.

    From the Division of Hypertension, UCLA Medical Center for Health Sciences, Los Angeles, California U.S.A.
    Search for articles by this author
  • Morton H. Maxwell
    Correspondence
    Address for reprints: Morton H. Maxwell, MD, 10921 Wilshire Boulevard, Suite 709, Los Angeles, California 90024.
    Affiliations
    From the Department of Medicine and the Center for Aging, University of Alabama, Birmingham, Alabama U.S.A.

    From the Division of Hypertension, UCLA Medical Center for Health Sciences, Los Angeles, California U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      After a 3-week placebo lead-in (Period 1), 78 patients with sitting diastolic blood pressures (BPs) of ≥90 and ≤105 mm Hg entered a 4-week period (Period 2) during which they received triamterene (TMT) 37.5 mg/hydrochlorothiazide (HCTZ) 25 mg/day.
      Four weeks of therapy with TMT 37.5 mg/ HCTZ 25 mg resulted in a statistically significant decrease in mean BP of Math Eq. Mean BP changed from Math Eq. Fifty-nine percent of patients were classified as responders as defined by study criteria. An additional 4 weeks of therapy (Period 3) for responders produced no further change in BP.
      Nonresponders as a group continued to have a further decrease in BP in Period 3. However, only patients in whom therapy was transferred to TMT 75 mg/HCTZ 50 mg had a statistically significant decrease. All patients who changed to the higher dose combination achieved goal BP by the end of the study. Of the nonresponders who continued to take TMT 37.5 mg/HCTZ 25 mg, 69% achieved goal diastolic BP by the end of Period 3. Three patients were withdrawn because of adverse experiences, 1 of which was considered treatment related. Of 58 reports of adverse experiences, 8 were considered possibly related and 2 probably related to therapy. There was a total of 8 clinically significant abnormal laboratory values, 1 of which was considered to have a possible relation to therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect